Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study - 01/03/24
Doi : 10.1016/j.jaad.2024.01.070
Rachel M. Reardon, BS a, b, Katherine L. Perlman, MPH a, c, Maria S. Asdourian, MPhil a, b, Nishi Shah, BS a, Ted V. Jacoby, BS a, Leah L. Thompson, MD a, Kerry L. Reynolds, MD d, Yevgeniy R. Semenov, MD, MA a, Steven T. Chen, MD, MPH, MS-HPEd a, b, ⁎ 
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
b Harvard Medical School, Boston, Massachusetts
c University of Illinois College of Medicine, Chicago, Illinois
d Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
∗Correspondence to: Steven T. Chen, MD, MPH, MS-HPEd, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, 50 Staniford St, Ste 200, Boston, MA 02114Department of DermatologyMassachusetts General Hospital and Harvard Medical School50 Staniford StSte 200BostonMA02114
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 01 March 2024
Key words : dermatologic immune-related adverse events, immune checkpoint inhibitor, immunotherapy, oncology
| Authors Reardon and Perlman contributed equally to this work. |
|
| Funding sources: Dermatology Foundation Medical Dermatology Career Development Award (Dr Chen). |
|
| Elements of this work to be included in a presentation at the World Congress of Dermatology, Singapore, July 7 2023. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Approved by the Institutional Review Board of Mass General Brigham (#2017P000501). |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?